GlobeNewswire Clinical StudiesOriginal article
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
Phase 3rugonersenPositive
AI Analysis
Summary
Oak Hill Bio announced the dosing of the first participant in BEACON, a Phase 3 clinical trial evaluating rugonersen for Angelman syndrome treatment.
Clinical Trial Data
Phase
3
Outcome Details
First participant dosed in BEACON Phase 3 trial
Importance:6/10
Sentiment:
0.30
rare diseaseASOPhase 3clinical trialAngelman syndrome
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 28, 2026 12:00 PM